Iqymune

Human Normal Immunoglobulin, the active ingredient in Iqymune, is a Immunoglobulin (human) presented as a solution for injection for intravenous use. It treats immunodeficiency disorders by supplying pooled IgG antibodies to patients with deficient immune function.

GNH USA supplies Iqymune as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iqymune, a human immunoglobulin therapy, is used to manage conditions involving impaired antibody production.

- Primary immunodeficiency diseases: provides replacement IgG to reduce infection frequency. - Secondary immunodeficiency (e.g., chemotherapy‑induced): supplies antibodies to support immune defense. - Bone marrow transplant patients: offers passive immunity during engraftment.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Fever: transient elevation of body temperature. - Chills: sensation of cold with shivering. - Nausea: feeling of queasiness. - Fatigue: general tiredness post‑infusion. - Infusion‑related reactions: flushing, erythema, or mild hypotension.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical care. - Thromboembolic events: blood clot formation in vessels. - Acute renal failure: sudden loss of kidney function. - Aseptic meningitis: inflammation of meninges without infection. - Severe hemolysis: rapid destruction of red blood cells. - Thrombocytopenia: markedly low platelet count.

Before initiating therapy, assess patient IgG levels and renal function.

- Assess IgG levels: determine baseline and monitor trough levels. - Monitor infusion reactions: observe vital signs during and after infusion. - Screen for IgA deficiency: avoid in patients with anti‑IgA antibodies. - Caution in hypercoagulable states: evaluate risk of thrombosis. - Adjust for renal impairment: consider slower infusion rates. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iqymune may interact with other agents that affect immune function or coagulation.

Major Interactions (Avoid): - Live vaccines: reduced efficacy when administered concurrently. - Other IVIG products: risk of immunoglobulin overload. - High‑dose aspirin: increased risk of renal impairment.

Moderate Interactions (Monitor Closely): - Corticosteroids: may augment infection risk. - Anticoagulants (e.g., warfarin): possible alteration of INR values. - Diuretics: heightened potential for renal dysfunction.